Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 May;73(5):1351–1358. doi: 10.1172/JCI111338

Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model.

S E Shoelson, K S Polonsky, A Zeidler, A H Rubenstein, H S Tager
PMCID: PMC425157  PMID: 6371057

Abstract

We have already demonstrated that a hyperinsulinemic, diabetic subject secreted an abnormal insulin in which serine replaced phenylalanine B24 (Shoelson S., M. Fickova, M. Haneda, A. Nahum, G. Musso, E. T. Kaiser, A. H. Rubenstein, and H. Tager. 1983. Proc. Natl. Acad. Sci. USA. 80:7390-7394). High performance liquid chromatography analysis now shows that the circulating insulin in several other family members also consists of a mixture of the abnormal human insulin B24 (Phe----Ser) and normal human insulin in a ratio of approximately 9.5:1 during fasting. Although all affected subjects show fasting hyperinsulinemia, only the propositus and her father are overtly diabetic. Analysis of the serum insulin from two nondiabetic siblings revealed that normal insulin increased from approximately 2 to 15% of total serum insulin after the ingestion of glucose and that the proportion of the normal hormone plateaued or fell while the level of total insulin continued to rise. Animal studies involving the graded intraportal infusion of equimolar amounts of semisynthetic human [SerB24]-insulin and normal human insulin in pancreatectomized dogs (to simulate the secretion of insulin due to oral glucose in man) also showed both a rise in the fraction of normal insulin that reached the periphery and the attainment of a brief steady state in this fraction while total insulin levels continued to rise. Separate experiments documented a decreased hepatic extraction, a decreased metabolic clearance rate, and an increased plasma half-life of human [SerB24]-insulin within the same parameters as those determined for normal human insulin. These results form a basis for considering (a) the differential clearance of low activity abnormal insulins and normal insulin from the circulation in vivo, and (b) the causes of hyperinsulinemia in both diabetic and nondiabetic individuals who secrete abnormal human insulins.

Full text

PDF
1351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assoian R. K., Thomas N. E., Kaiser E. T., Tager H. S. [LeuB24]insulin and [AlaB24]insulin: altered structures and cellular processing of B24-substituted insulin analogs. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5147–5151. doi: 10.1073/pnas.79.17.5147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonora E., Zavaroni I., Coscelli C., Butturini U. Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metabolism. 1983 May;32(5):438–446. doi: 10.1016/0026-0495(83)90004-5. [DOI] [PubMed] [Google Scholar]
  3. Faber O. K., Christensen K., Kehlet H., Madsbad S., Binder C. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab. 1981 Sep;53(3):618–621. doi: 10.1210/jcem-53-3-618. [DOI] [PubMed] [Google Scholar]
  4. Given B. D., Mako M. E., Tager H. S., Baldwin D., Markese J., Rubenstein A. H., Olefsky J., Kobayashi M., Kolterman O., Poucher R. Diabetes due to secretion of an abnormal insulin. N Engl J Med. 1980 Jan 17;302(3):129–135. doi: 10.1056/NEJM198001173020301. [DOI] [PubMed] [Google Scholar]
  5. Haneda M., Chan S. J., Kwok S. C., Rubenstein A. H., Steiner D. F. Studies on mutant human insulin genes: identification and sequence analysis of a gene encoding [SerB24]insulin. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6366–6370. doi: 10.1073/pnas.80.20.6366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Heding L. G. Insulin, C-peptide, and proinsulin in nondiabetics and insulin-treated diabetics. Characterization of the proinsulin in insulin-treated diabetics. Diabetes. 1978;27 (Suppl 1):178–183. doi: 10.2337/diab.27.1.s178. [DOI] [PubMed] [Google Scholar]
  7. Inouye K., Watanabe K., Tochino Y., Kanaya T., Kobayashi M., Shigeta Y. Semisynthesis and biological properties of the [B24-leucine]-, [B25-leucine[- and [B24-leucine, B25-leucine]-analogues of human insulin. Experientia. 1981;37(8):811–813. doi: 10.1007/BF01985653. [DOI] [PubMed] [Google Scholar]
  8. Jaspan J., Polonsky K. Glucose ingestion in dogs alters the hepatic extraction of insulin. In vivo evidence for a relationship between biologic action and extraction of insulin. J Clin Invest. 1982 Mar;69(3):516–525. doi: 10.1172/JCI110477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Keefer L. M., Piron M. A., De Meyts P., Gattner H. G., Diaconescu C., Saunders D., Brandenburg D. Impaired negative cooperativity of the semisynthetic analogues human [LeuB24]- and [LeuB25]-insulins. Biochem Biophys Res Commun. 1981 Jun 16;100(3):1229–1236. doi: 10.1016/0006-291x(81)91955-0. [DOI] [PubMed] [Google Scholar]
  10. Kobayashi M., Ohgaku S., Iwasaki M., Maegawa H., Shigeta Y., Inouye K. Characterization of [LeuB-24]- and [LeuB-25]-insulin analogues. Receptor binding and biological activity. Biochem J. 1982 Sep 15;206(3):597–603. doi: 10.1042/bj2060597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kuzuya H., Blix P. M., Horwitz D. L., Steiner D. F., Rubenstein A. H. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes. 1977 Jan;26(1):22–29. doi: 10.2337/diab.26.1.22. [DOI] [PubMed] [Google Scholar]
  12. Kwok S. C., Chan S. J., Rubenstein A. H., Poucher R., Steiner D. F. Loss of a restriction endonuclease cleavage site in the gene of a structurally abnormal human insulin. Biochem Biophys Res Commun. 1981 Feb 12;98(3):844–849. doi: 10.1016/0006-291x(81)91188-8. [DOI] [PubMed] [Google Scholar]
  13. Kwok S. C., Steiner D. F., Rubenstein A. H., Tager H. S. Identification of a point mutation in the human insulin gene giving rise to a structurally abnormal insulin (insulin Chicago). Diabetes. 1983 Sep;32(9):872–875. doi: 10.2337/diab.32.9.872. [DOI] [PubMed] [Google Scholar]
  14. Polonsky K. S., Jaspan J. B., Berelowitz M., Emmanouel D. S., Dhorajiwala J. Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog. J Clin Invest. 1981 Nov;68(5):1149–1157. doi: 10.1172/JCI110359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Polonsky K., Jaspan J., Emmanouel D., Holmes K., Moossa A. R. Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Acta Endocrinol (Copenh) 1983 Mar;102(3):420–427. doi: 10.1530/acta.0.1020420. [DOI] [PubMed] [Google Scholar]
  16. Polonsky K., Jaspan J., Pugh W., Cohen D., Schneider M., Schwartz T., Moossa A. R., Tager H., Rubenstein A. H. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. J Clin Invest. 1983 Sep;72(3):1114–1123. doi: 10.1172/JCI111036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Robbins D. C., Blix P. M., Rubenstein A. H., Kanazawa Y., Kosaka K., Tager H. S. A human proinsulin variant at arginine 65. Nature. 1981 Jun 25;291(5817):679–681. doi: 10.1038/291679a0. [DOI] [PubMed] [Google Scholar]
  18. Savage P. J., Flock E. V., Mako M. E., Blix P. M., Rubenstein A. H., Bennett P. H. C-Peptide and insulin secretion in Pima Indians and Caucasians: constant fractional hepatic extraction over a wide range of insulin concentrations and in obesity. J Clin Endocrinol Metab. 1979 Apr;48(4):594–598. doi: 10.1210/jcem-48-4-594. [DOI] [PubMed] [Google Scholar]
  19. Shoelson S., Fickova M., Haneda M., Nahum A., Musso G., Kaiser E. T., Rubenstein A. H., Tager H. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7390–7394. doi: 10.1073/pnas.80.24.7390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shoelson S., Haneda M., Blix P., Nanjo A., Sanke T., Inouye K., Steiner D., Rubenstein A., Tager H. Three mutant insulins in man. Nature. 1983 Apr 7;302(5908):540–543. doi: 10.1038/302540a0. [DOI] [PubMed] [Google Scholar]
  21. Tager H., Given B., Baldwin D., Mako M., Markese J., Rubenstein A., Olefsky J., Kobayashi M., Kolterman O., Poucher R. A structurally abnormal insulin causing human diabetes. Nature. 1979 Sep 13;281(5727):122–125. doi: 10.1038/281122a0. [DOI] [PubMed] [Google Scholar]
  22. Tager H., Thomas N., Assoian R., Rubenstein A., Saekow M., Olefsky J., Kaiser E. T. Semisynthesis and biological activity of porcine [LeuB24]insulin and [LeuB25]insulin. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3181–3185. doi: 10.1073/pnas.77.6.3181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Terris S., Steiner D. F. Binding and degradation of 125I-insulin by rat hepatocytes. J Biol Chem. 1975 Nov 10;250(21):8389–8398. [PubMed] [Google Scholar]
  24. Terris S., Steiner D. F. Retention and degradation of 125I-insulin by perfused livers from diabetic rats. J Clin Invest. 1976 Apr;57(4):885–896. doi: 10.1172/JCI108365. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES